Novo Nordisk A/s Share Price Today
(NASDAQ: NVO)

Name: Novo Nordisk A/s Share Price Today (NASDAQ: NVO) - Novo Nordisk A/s Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Novo Nordisk A/s share price is $85.19 & ₹7,366.98 as on 29 Jan 2025, 2.30 'hrs' IST

$85.19

▲

-2.32

(-2.65%)

Market is closed - opens 8 PM, 29 Jan 2025

View live Novo Nordisk A/s share price in Dollar and Rupees. Guide to invest in Novo Nordisk A/s stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Novo Nordisk A/s, along with analyst recommendations, forecasts, and comprehensive financials.

Novo Nordisk A/s share price movements

Today's Low: $84.64
Today's High: $86.80
$85.19
0.65%
Downside
Day's Volatility :2.49%
Upside
1.86%
52 Weeks Low: $78.17
52 Weeks High: $148.15
$85.19
8.24%
Downside
52 Weeks Volatility :47.24%
Upside
42.5%

Novo Nordisk A/s (NVO) Returns

Period	Novo Nordisk A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	-24.77%	-1.3%	0.0%
6 Months	-35.77%	-2.4%	0.0%
1 Year	-21.86%	4.5%	0.0%
3 Years	70.6%	12.3%	-10.1%

Novo Nordisk A/s (NVO) Key Statistics

in dollars & INR

Previous Close	$87.51
Open	$86.07
Today's High	$86.8025
Today's Low	$84.64
Market Capitalization	$358.0B
Today's Volume	$9.3M
52 Week High	$148.15
52 Week Low	$78.17
Revenue TTM	$270.6B
EBITDA	$127.4B
Earnings Per Share (EPS)	$2.96
PE Ratio	29.56
Dividend Yield	1.64%
Profit Margin	35.01%
Quarterly Earnings Growth YOY	0.22%
Return On Equity TTM	88.73%

How to invest in Novo Nordisk A/s Stock (NVO) from India?

It is very easy for Indian residents to invest directly in Novo Nordisk A/s from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Novo Nordisk A/s stock in both Indian Rupees (INR) and US Dollars (USD). Search for Novo Nordisk A/s or NVO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Novo Nordisk A/s or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Novo Nordisk A/s shares which would translate to 0.010 fractional shares of Novo Nordisk A/s as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Novo Nordisk A/s, in just a few clicks!

Returns in Novo Nordisk A/s (NVO) for Indian investors in Rupees

The Novo Nordisk A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Novo Nordisk A/s investment value today

Current value as on today

₹82,180

Returns

₹17,820

(-17.82%)

Returns from Novo Nordisk A/s Stock

₹21,858 (-21.86%)

Dollar Returns

₹4,039 (+4.04%)

Indian investors sentiment towards Novo Nordisk A/s (NVO)

3.79%

Period: Dec 29, 2025 to Jan 28, 2025. Change in 30 Days versus previous period

Investment in Novo Nordisk A/s Shares from India has grown by 3.79% over the past 30 days, indicating increased transactional activity.

Period: Dec 29, 2025 to Jan 28, 2025. Change in 30 Days versus previous period

Search interest for Novo Nordisk A/s Stock from India on INDmoney has increased by 3% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Novo Nordisk A/s Stock (NVO Ticker)

Name	Shares Held	Change in Shares	% of Assets
Axis Innovation Fund Direct Growth	8068	-440.27	0.49%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	4861	-2177.14	2.26%

Global Institutional Holdings in Novo Nordisk A/s

Jennison Associates LLC
0.45%
FMR Inc
0.40%
Morgan Stanley - Brokerage Accounts
0.32%
Bank of America Corp
0.32%
Fisher Asset Management, LLC
0.30%
Fayez Sarofim & Company
0.28%

Analyst Recommendation on Novo Nordisk A/s

Buy

62%Buy

31%Hold

6%Sell

Based on 32 Wall street analysts offering stock ratings for Novo Nordisk A/s(by analysts ranked 0 to 5 stars)

Based on 32 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Novo Nordisk A/s Stock (NVO)

What analysts predicted

Upside of 31.53%

Target:

$112.05

Current:

$85.19

Insights on Novo Nordisk A/s Stock (Ticker Symbol: NVO)

Price Movement
In the last 7 days, NVO stock has moved up by 5.7%
Increasing Revenue
Novo Nordisk A/S has shown consistent revenue growth over the last three quarters. The company's revenue increased from $65.34 billion to $71.31 billion, representing an average growth of 4.3% each quarter.
Increasing Net Profit
Novo Nordisk A/s has shown consistent profit growth over the last two quarters. Their net profit increased from $20.05 billion to $27.30 billion, marking an average rise of 26.6% per quarter.
NVO vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 24.8% return, outperforming this stock by 46.7%
NVO vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 228.4% return, outperforming this stock by 152.3%
Price to Sales
Novo Nordisk A/S has a Price-to-Sales Ratio of 1.4, meaning investors are willing to pay $1.40 for every $1 of sales the company generates. In comparison, Eli Lilly And Company has a significantly higher Price-to-Sales Ratio of 17.7, indicating that investors are willing to pay $17.70 for every $1 of sales. This suggests that investors value Novo Nordisk's sales lower than those of Eli Lilly.

NVO Novo Nordisk A/s Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$17.0B	↑ 0.12%
Net Income	$5.9B	↑ 1.31%
Net Profit Margin	34.54%	↑ 0.4%

	FY19	Y/Y Change
Revenue	$18.1B	↑ 9.11%
Net Income	$5.8B	↑ 0.84%
Net Profit Margin	31.92%	↓ 2.62%

	FY20	Y/Y Change
Revenue	$20.7B	↑ 4.04%
Net Income	$6.9B	↑ 8.18%
Net Profit Margin	33.19%	↑ 1.27%

	FY21	Y/Y Change
Revenue	$21.4B	↑ 10.91%
Net Income	$7.3B	↑ 13.33%
Net Profit Margin	33.92%	↑ 0.73%

	FY22	Y/Y Change
Revenue	$25.2B	↑ 25.68%
Net Income	$7.9B	↑ 16.27%
Net Profit Margin	31.38%	↓ 2.54%

	FY23	Y/Y Change
Revenue	$34.0B	↑ 31.26%
Net Income	$12.3B	↑ 50.71%
Net Profit Margin	36.03%	↑ 4.65%

	Q2 FY23	Q/Q Change
Revenue	$7.9B	↑ 1.75%
Net Income	$2.8B	↓ 1.95%
Net Profit Margin	35.78%	↓ 1.35%

	Q3 FY23	Q/Q Change
Revenue	$8.4B	↑ 8.16%
Net Income	$3.2B	↑ 15.7%
Net Profit Margin	38.27%	↑ 2.49%

	Q4 FY23	Q/Q Change
Revenue	$9.6B	↑ 12.14%
Net Income	$3.2B	↓ 2.29%
Net Profit Margin	33.35%	↓ 4.92%

	Q1 FY24	Q/Q Change
Revenue	$9.5B	↓ 0.78%
Net Income	$3.7B	↑ 15.68%
Net Profit Margin	38.88%	↑ 5.53%

	Q2 FY24	Q/Q Change
Revenue	$9.8B	↑ 4.15%
Net Income	$2.9B	↓ 21.08%
Net Profit Margin	29.46%	↓ 9.42%

	Q3 FY24	Q/Q Change
Revenue	$71.3B	↑ 4.78%
Net Income	$27.3B	↑ 36.16%
Net Profit Margin	38.28%	↑ 8.82%

	FY18	Y/Y Change
Profit	$14.4B	↑ 0.16%

	FY19	Y/Y Change
Profit	$15.2B	↑ 8.19%

	FY20	Y/Y Change
Profit	$17.3B	↑ 4.0%

	FY21	Y/Y Change
Profit	$17.8B	↑ 10.5%

	FY22	Y/Y Change
Profit	$21.1B	↑ 26.77%

	FY23	Y/Y Change
Profit	$28.8B	↑ 32.32%

	Q2 FY23	Q/Q Change
Profit	$6.8B	↑ 2.79%

	Q3 FY23	Q/Q Change
Profit	$7.0B	↑ 5.54%

	Q4 FY23	Q/Q Change
Profit	$8.2B	↑ 13.94%

	Q1 FY24	Q/Q Change
Profit	$8.1B	↓ 0.74%

	Q2 FY24	Q/Q Change
Profit	$8.3B	↑ 4.24%

	Q3 FY24	Q/Q Change
Profit	$60.0B	↑ 3.84%

	FY18	Y/Y Change
Operating Cash Flow	$6.8B	↑ 8.38%
Investing Cash Flow	$-1.8B	↑ 83.84%
Financing Cash Flow	$-5.3B	↓ 3.27%

	FY19	Y/Y Change
Operating Cash Flow	$7.0B	↑ 4.85%
Investing Cash Flow	$-1.7B	↓ 4.73%
Financing Cash Flow	$-5.3B	↑ 2.79%

	FY20	Y/Y Change
Operating Cash Flow	$8.5B	↑ 11.05%
Investing Cash Flow	$-3.7B	↑ 94.94%
Financing Cash Flow	$-5.3B	↓ 9.13%

	FY21	Y/Y Change
Operating Cash Flow	$8.4B	↑ 5.87%
Investing Cash Flow	$-4.8B	↑ 40.87%
Financing Cash Flow	$-3.9B	↓ 20.94%

	FY22	Y/Y Change
Operating Cash Flow	$11.2B	↑ 43.43%
Investing Cash Flow	$-3.5B	↓ 21.16%
Financing Cash Flow	$-7.4B	↑ 103.18%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$4.2B	↓ 4.15%
Investing Cash Flow	$-2.3B	↑ 139.69%
Financing Cash Flow	$-1.8B	↓ 38.95%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$5.9B	↑ 43.35%
Investing Cash Flow	$-4.2B	↑ 83.12%
Financing Cash Flow	$-2.8B	↑ 57.53%

Novo Nordisk A/s Technicals Summary

Sell

Neutral

Buy

Novo Nordisk A/s is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Novo Nordisk A/s (NVO) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novo Nordisk A/s	-0.63%	-35.77%	-21.86%	70.6%	180.09%
Eli Lilly And Company	4.03%	0.09%	24.81%	228.05%	476.48%
Johnson & Johnson	4.91%	-4.73%	-5.28%	-12.72%	1.01%
Merck & Co. Inc.	-0.94%	-13.86%	-19.9%	19.6%	14.06%
Abbvie Inc	-0.79%	-5.67%	6.0%	27.7%	115.76%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novo Nordisk A/s	29.56	29.56	1.47	23.08	0.89	0.21	0.02	27.07
Eli Lilly And Company	86.65	86.65	0.77	12.92	0.65	0.14	0.01	15.83
Johnson & Johnson	26.45	26.45	0.93	10.55	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.49	20.49	0.07	7.67	0.28	0.11	0.03	17.58
Abbvie Inc	61.42	61.42	0.4	10.58	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novo Nordisk A/s	Buy	$358.0B	180.09%	29.56	35.01%
Eli Lilly And Company	Buy	$723.9B	476.48%	86.65	20.48%
Johnson & Johnson	Buy	$368.1B	1.01%	26.45	16.74%
Merck & Co. Inc.	Buy	$247.8B	14.06%	20.49	19.23%
Abbvie Inc	Buy	$312.6B	115.76%	61.42	9.22%

Novo Nordisk A/s Dividend announcements

Novo Nordisk A/s Dividends September, 2024
In the quarter ending September,2024. Novo Nordisk A/s has declared dividend of $0.51
Read More

About Novo Nordisk A/s

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases; with IMMvention Therapeutix, Inc to develop oral therapies for sickle cell disease and other chronic diseases; and with Valo Health, Inc. to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Organization	Novo Nordisk A/s
Employees	71880
CEO	Mr. Lars Fruergaard Jorgensen
Industry	Health Technology

Management People of Novo Nordisk A/s

Name	Title
Mr. Lars Fruergaard Jorgensen	President, CEO & Member of Management Board
Mr. Karsten Munk Knudsen	Executive VP, CFO & Member of the Management Board
Mr. Henrik Ehlers Wulff	Executive VP of Product Supply, Quality & IT and Member of the Management Board
Ms. Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board
Dr. Martin Holst Lange	Executive VP of Development & Member of the Management Board
Dr. Marcus Schindler Ph.D.	EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board
Mr. Maziar Mike Doustdar	Executive VP of International Operations & Member of the Management Board
Mr. Douglas J. Langa	Executive VP of North America Operations & Member of Management Board
Mr. Ludovic Helfgott	Executive VP, Head of Rare Disease & Member of Management Board
Ms. Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board

Important FAQs about investing in NVO Stock from India :

What is Novo Nordisk A/s share price today?

Novo Nordisk A/s share price today stands at $85.19, Open: $86.07 ; Previous Close: $87.51 ; High: $86.80 ; Low: $84.64 ; 52 Week High: $148.15 ; 52 Week Low: $78.17. The stock opens at $86.07, after a previous close of $87.51. The stock reached a daily high of $86.80 and a low of $84.64, with a 52-week high of $148.15 and a 52-week low of $78.17.

Can Indians buy Novo Nordisk A/s shares?

Yes, Indians can invest in the Novo Nordisk A/s (NVO) from India.

With INDmoney, you can buy Novo Nordisk A/s at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Novo Nordisk A/s at zero transaction cost.

How can I buy Novo Nordisk A/s shares from India?

It is very easy to buy Novo Nordisk A/s from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Novo Nordisk A/s (NVO) be purchased?

Yes, you can buy fractional shares of Novo Nordisk A/s with INDmoney app.

What are the documents required to start investing in Novo Nordisk A/s stocks?

To start investing in Novo Nordisk A/s, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.